Literature DB >> 15337372

NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy.

S P Kalra1, P S Kalra.   

Abstract

Neuropeptide Y is the most potent physiological appetite transducer known. The NPY network is the conductor of the hypothalamic appetite regulating orchestra in the arcuate nucleus-paraventricular nucleus (ARC-PVN) of the hypothalamus. NPY and cohorts, AgrP, GABA and adrenergic transmitters, initiate appetitive drive directly through Y1, Y5, GABAA and alpha1 receptors, co-expressed in the magnocellular PVN (mPVN) and ARC neurons and by simultaneously repressing anorexigenic melanocortin signaling in the ARC-PVN axis. The circadian and ultradian rhythmicities in NPY secretion imprint the daily circadian and episodic feeding patterns. Although a number of afferent hormonal signals from the periphery can directly modulate NPYergic signaling, the reciprocal circadian and ultradian rhythmicities of anorexigenic leptin from adipocytes and orexigenic ghrelin from stomach, encode a corresponding pattern of NPY discharge for daily meal patterning. Subtle and progressive derangements produced by environmental and genetic factors in this exquisitely intricate temporal relationship between the two opposing humoral signals and the NPY network promote hyperphagia and abnormal rate of weight gain culminating in obesity and attendant metabolic disorders. Newer insights at cellular and molecular levels demonstrate that a breakdown of the integrated circuit due both to high and low abundance of NPY at target sites, underlies hyperphagia and increased adiposity. Consequently, interruption of NPYergic signaling at a single locus with NPY receptor antagonists may not be the most efficacious therapy to suppress hyperphagia and obesity. Central leptin gene therapy in rodents has been shown to subjugate, i.e. bring under homeostatic control, NPYergic signaling and suppress the age-related and dietary obesity for extended periods and thus shows promise as a newer treatment modality to curb the pandemic of obesity and metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337372     DOI: 10.1016/j.npep.2004.06.003

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  43 in total

1.  Meal patterns and hypothalamic NPY expression during chronic social stress and recovery.

Authors:  Susan J Melhorn; Eric G Krause; Karen A Scott; Marie R Mooney; Jeffrey D Johnson; Stephen C Woods; Randall R Sakai
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-07-07       Impact factor: 3.619

Review 2.  The neuroendocrine basis of lactation-induced suppression of GnRH: role of kisspeptin and leptin.

Authors:  M Susan Smith; Cadence True; K L Grove
Journal:  Brain Res       Date:  2010-08-19       Impact factor: 3.252

Review 3.  Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology.

Authors:  Luigi Racioppi; Anthony R Means
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

Review 4.  Paraventricular nucleus, stress response, and cardiovascular disease.

Authors:  Eduardo E Benarroch
Journal:  Clin Auton Res       Date:  2005-08       Impact factor: 4.435

Review 5.  To subjugate NPY is to improve the quality of life and live longer.

Authors:  Satya P Kalra; Pushpa S Kalra
Journal:  Peptides       Date:  2007-01-09       Impact factor: 3.750

Review 6.  Low abundance of NPY in the hypothalamus can produce hyperphagia and obesity.

Authors:  Michael G Dube; Satya P Kalra; Pushpa S Kalra
Journal:  Peptides       Date:  2007-01-12       Impact factor: 3.750

7.  Maternal low-protein diet up-regulates the neuropeptide Y system in visceral fat and leads to abdominal obesity and glucose intolerance in a sex- and time-specific manner.

Authors:  Ruijun Han; Aiyun Li; Lijun Li; Joanna B Kitlinska; Zofia Zukowska
Journal:  FASEB J       Date:  2012-04-25       Impact factor: 5.191

8.  Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: Implications for treatment resistance.

Authors:  Benedetta Bigio; Aleksander A Mathé; Vasco C Sousa; Danielle Zelli; Per Svenningsson; Bruce S McEwen; Carla Nasca
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-27       Impact factor: 11.205

9.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

10.  Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.

Authors:  Min Hee Park; Hee Kyung Jin; Woo-Kie Min; Won Woo Lee; Jeong Eun Lee; Haruhiko Akiyama; Herbert Herzog; Grigori N Enikolopov; Edward H Schuchman; Jae-sung Bae
Journal:  EMBO J       Date:  2015-04-27       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.